Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc.

XENE · Nasdaq

Xenon Pharmaceuticals Inc. (XENE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Xenon Pharmaceuticals Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 82 days

EPS estimate

-1.18

Revenue estimate

0

Past earnings

06 Aug 2026
EPS actual
-1.11 (+2.8%)
estimate -1.14
Revenue actual
0 (-100.0%)
estimate 1.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
-1.17 (+0.8%)
estimate -1.18
Revenue actual
0 (-100.0%)
estimate 1.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
26 Feb 2026
EPS actual
-1.31 (-9.9%)
estimate -1.19
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Xenon Pharmaceuticals beat consensus estimates for EPS but missed on revenue in its latest earnings report, with EPS of $-1.11 versus an estimate of $-1.1415 and revenue of $0 falling 100.0% short of the $1.67 million expected. In the prior quarter, EPS also came in ahead of expectations while revenue again fell short of estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Exchange
Nasdaq
CEO
Ian C. Mortimer
Employees
316
IPO date
05 Nov 2014
ISIN
CA98420N1050
Website
xenon-pharma.com

Frequently asked questions

When does Xenon Pharmaceuticals Inc. (XENE) next report earnings?

Xenon Pharmaceuticals Inc. (XENE) is scheduled to report earnings on November 11, 2026.

What was Xenon Pharmaceuticals Inc.'s most recent earnings date?

Xenon Pharmaceuticals Inc. (XENE) last reported earnings on August 6, 2026.

Where is Xenon Pharmaceuticals Inc. stock listed?

Xenon Pharmaceuticals Inc. (XENE) is listed on Nasdaq.